ArticleCommunications biology2025
Lactobacillus rhamnosus GG maintains gut microbiota stability and promotes intestinal adaptation via activated intestinal farnesoid X receptor signaling in short bowel syndrome.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Understanding the gut microbiota to shape the future of intestinal failure care: a systematic review of the evidence.European journal of pediatrics · 2026Pooled it
- Article
- Next-generation probiotics: an outlook into current applications and future developments.Nature reviews. Microbiology · 2026Review
- The Gut-Brain-Skin Axis: Systemic Effects of Functional Ingredients in Healthy Skin Aging.International journal of molecular sciences · 2026Review
- AI-2 combined with Lactobacillus rhamnosus GG remodels gut microbiota structure to alleviate intestinal oxidative stress injury in a mouse necrotizing enterocolitis model.Journal of translational medicine · 2026Article
- Effect of Probiotics on the Gut-Mammary Pathway: Implications on Infant Microbiota Transfer and Development.Current nutrition reports · 2026Review
- Article
- Gut Microbiome Dynamics in Food Allergy Development Across the Lifespan: Microbial Mechanisms, Host Interactions, and Therapeutic Perspectives.Microorganisms · 2026Review
- Pre-, Pro-, Post- and Synbiotics in Pediatric Short Bowel Syndrome: A Narrative Review of Current Evidence.Children (Basel, Switzerland) · 2026Review
- Time-dependent Lactiplantibacillus plantarum (LP) AS21 intervention enhances mesalazine efficacy by modulating gut microbiota and host immunometabolic responses in DSS-induced colitis.Journal of translational medicine · 2026Article
- Article
- Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Assessment of the Isolated and Combined Impact of β-Glucan andNutrients · 2025Article
- Microbiota-oriented strategies to mitigate parenteral nutrition-related complications in intestinal failure: A narrative review.Intestinal Failure (New York, N.Y.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal farnesoid X receptor (FXR) signaling plays a critical role in maintaining intestinal microbiota stability. In this study, we investigated the probiotic Lactobacillus rhamnosus GG (LGG) and its ability to promote intestinal adaptation and stabilize the gut microbiota by activating intestinal FXR signaling in short bowel syndrome (SBS). In patients with type I SBS, fecal microbial α-diversity was decreased, Proteobacteria abundance was increased, and Firmicutes, Actinobacteria, and Bacteroidetes abundance levels were decreased. In vitro, LGG supernatant (LGGs) upregulated FXR expression in Caco-2 cells and ileum organoids. In vivo, LGG supplementation significantly improved intestinal morphology in wild-type (WT) SBS mice, including increased villus height, crypt depth and goblet cell numbers. Serum fibroblast growth factor 15 (FGF15) levels increased and fecal Proteobacteria abundance decreased, while secondary bile acids rose and primary bile acids declined in WT SBS mice after LGG supplementation. In addition, LGG supplementation also increased occludin and FXR expression in WT SBS mice, but not in intestinal FXR knockout (FXR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.